RHONE-POULENC RORER INVESTMENTS IN CELLULAR/GENE THERAPIES WILL TOTAL $300 MIL. BY END OF 1995; GENCELL WILL OVERSEE NETWORK WITH SIX THERAPIES IN CLINIC
Executive Summary
Rhone-Poulenc Rorer is building a biotech network of cellular and gene therapy collaborations in which the company will have invested $300 mil. by the end of 1995.